Abstract
Considerable evidence has accumulated indicating that cultured human or rodent tumor cells can be successfully transduced with cytokine genes and selected in the appropriate antibiotic-containing culture media. The selected transductants are generally able to secrete the cytokine coded for by the transduced gene, and in many cases, substantial levels (e.g., ng quantities) of the cytokine are produced. Using retroviral vectors, it has been possible to obtain stably transduced tumor cells with a variety of cytokine genes (1-4). These tumor cells have been used for immunotherapy of cancer in numerous animal models of tumor growth or metastasis, and more recently, in vaccination protocols in patients with cancer. One possible criticism that can be leveled at this type of vaccination approach is that cultured, genetically modified, and selected tumor cells might have phenotypic characteristics that are substantially different from those of unmodified tumor cells. Since retroviral vectors are often used for transduction, it is also possible that viral antigens expressed on transduced tumor cells contribute to the immune response generated as a result of vaccination. Also, primary cultures of human tumor cells are often difficult to establish and maintain.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R, and Gilboa, E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity J Exp Med. 172, 1217–1224.
Golumbek, P. T., Lazenby, A. J., Levitzky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M. (1990) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254, 713–716.
Gansbacher, B., Rosenthal, F. M., and Zier, K. (1993) Retroviral vector-mediated cytokine-gene transfer into tumor cells Cancer Invest 11, 345–354.
Jaffee, E. M., Dranoff, G., Cohen, L. K., Hauda, K. M., Clift S., Marshall, F. F., Mulligan, R C., and Pardoll, D. M. (1993) High efficiency gene transfer into primary human tumor explants without cell selection, Cancer Res 53, 2221–2226.
Lotze, M. T. and Rubin, J T. (1994) Gene therapy of cancer a pilot dtudy of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response Hum Gene Ther. 5, 41–55.
Tahara, H.and Lotze, M. T. (1995) IL-12 Gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum. Gene Ther 6, 1607–1624.
Elder, E M., Lotze, M. T., and Whiteside, T. L. (1996) Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum. Gene Ther. 7, 479–487.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Elder, E.M., Lotze, M.T., Whiteside, T.L. (1997). Methods for Generation of Genetically Modified Fibroblasts for Immunotherapy of Cancer. In: Robbins, P.D. (eds) Gene Therapy Protocols. Methods in Molecular Medicine, vol 7. Humana, Totowa, NJ. https://doi.org/10.1385/0-89603-484-4:349
Download citation
DOI: https://doi.org/10.1385/0-89603-484-4:349
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-0-89603-484-6
Online ISBN: 978-1-59259-591-4
eBook Packages: Springer Protocols